Last reviewed · How we verify
Oxybutynin chloride, extended-release
Oxybutynin chloride is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.
Oxybutynin chloride is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in spinal cord injury patients.
At a glance
| Generic name | Oxybutynin chloride, extended-release |
|---|---|
| Also known as | Antimuscarinic medication |
| Sponsor | US Department of Veterans Affairs |
| Drug class | Anticholinergic agent |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
By antagonizing M3 muscarinic receptors on detrusor muscle, oxybutynin decreases the frequency and amplitude of bladder contractions. The extended-release formulation provides sustained drug delivery over 24 hours, improving tolerability compared to immediate-release formulations while maintaining efficacy in reducing urinary urgency and incontinence episodes.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
- Neurogenic detrusor overactivity in spinal cord injury patients
Common side effects
- Dry mouth
- Constipation
- Dizziness
- Blurred vision
- Headache
- Somnolence
Key clinical trials
- Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
- Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg (PHASE1)
- Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg (PHASE1)
- Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg (PHASE1)
- Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg (PHASE1)
- A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition (PHASE3)
- Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy (NA)
- Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: